Jacob Bar-Tana

USPTO Granted Patents = 10 (Patent Applications = 2)

CIPO Patents = 1

EPO Patents = 4 (Patent Applications = 2)

Average Co-Inventor Count = 1.2

ph-index = 4

Forward Citations = 199(Granted Patents)

Company Filing History:

Yissum Research Development Company of the Hebrew University of Jerusalem Ltd.

Years Active: 1987-2021

Loading Chart...

10 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 11207285 - Diabetes treatment regimens using alpha, alpha-substituted long-chain amphipathic carboxylates (2021-12-28),

2. 10512624 - Long-chain amphipathic dicarboxylic acids for treatment of diabetes type-1 (2019-12-24),

3. 10479752 - Deuterated tetramethyl dioic acids, compositions comprising them and uses thereof (2019-11-19),

4. 6800772 - Carboxylic acids and derivatives thereof and pharmaceutical compositions containing them (2004-10-05),

5. 6303653 - Carboxylic acids and derivatives thereof and pharmaceutical compositions containing them (2001-10-16),

6. 6284903 - Carboxylic acids and derivatives thereof and pharmaceutical compositions containing them (2001-09-04),

7. 4908385 - .alpha.-halogenated dicarboxylic acids, pharmaceutical compositions and (1990-03-13),

8. 4711896 - .alpha., .omega.-dicarboxylic acids and medicaments which contain these (1987-12-08),

9. 4689344 - Long-chain .alpha.,.omega.-dicarboxylic acids and derivatives thereof (1987-08-25),

10. 4634795 - Long-chain .alpha.,.omega.-di-carboxylic acids and derivatives thereof (1987-01-06),

Title: The Innovative Contributions of Jacob Bar-Tana

Introduction

Jacob Bar-Tana is a prominent inventor based in Jerusalem, Israel. He has made significant contributions to the field of diabetes treatment, holding a total of 10 patents. His work focuses on innovative methods for managing diabetes, particularly type 1 and type 2 diabetes mellitus.

Latest Patents

Bar-Tana's latest patents include groundbreaking methods for treating type 2 diabetes mellitus using alpha, alpha-substituted long-chain amphipathic carboxylates. These methods involve administering a substituted long-chain dicarboxylic acid as an add-on therapy to standard anti-diabetic treatments. Additionally, he has developed methods for treating type 1 diabetes by using substituted long-chain amphipathic dicarboxylic acids, which can reduce the required dose of insulin or even eliminate the need for insulin administration in some patients.

Career Highlights

Throughout his career, Jacob Bar-Tana has worked with notable companies such as Epis S.A. and Yissum Research Development Company of the Hebrew University of Jerusalem Ltd. His innovative approaches have garnered attention in the medical community, contributing to advancements in diabetes care.

Collaborations

Bar-Tana has collaborated with esteemed colleagues, including Johannes Pill and Ernst-Christian Witte. These partnerships have further enhanced his research and development efforts in the field of diabetes treatment.

Conclusion

Jacob Bar-Tana's contributions to diabetes treatment through his innovative patents and collaborations highlight his role as a leading inventor in the medical field. His work continues to impact the lives of individuals living with diabetes, showcasing the importance of innovation in healthcare.

This text is generated by artificial intelligence and may not be accurate.